CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Nashville, Tennessee, United States and 16 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Nashville, Tennessee, United States and 41 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Nashville, Tennessee, United States and 75 other locations
at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...
Phase 1, Phase 2
Nashville, Tennessee, United States and 12 other locations
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...
Phase 1
Nashville, Tennessee, United States and 37 other locations
safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non...
Phase 1, Phase 2
Nashville, Tennessee, United States and 16 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...
Phase 1, Phase 2
Nashville, Tennessee, United States and 3 other locations
and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non...
Phase 1
Nashville, Tennessee, United States
of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse...
Phase 1, Phase 2
Nashville, Tennessee, United States and 29 other locations
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed orig...
Phase 4
Nashville, Tennessee, United States and 34 other locations
Clinical trials
Research sites
Resources
Legal